Baader Bank Aktiengesellschaft Reduces Position in BioNTech SE (NASDAQ:BNTX)

Baader Bank Aktiengesellschaft cut its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,400 shares of the company's stock after selling 3,881 shares during the period. BioNTech accounts for approximately 1.0% of Baader Bank Aktiengesellschaft's portfolio, making the stock its 13th largest holding. Baader Bank Aktiengesellschaft owned approximately 0.06% of BioNTech worth $15,994,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BNTX. Fred Alger Management LLC purchased a new position in shares of BioNTech during the third quarter worth about $59,485,000. Baillie Gifford & Co. grew its holdings in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after purchasing an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock worth $2,249,000 after purchasing an additional 7,340 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of BioNTech by 123.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company's stock worth $15,919,000 after purchasing an additional 74,119 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after purchasing an additional 33,375 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Up 1.7 %

Shares of BioNTech stock traded up $2.04 during midday trading on Thursday, reaching $123.20. 423,573 shares of the company's stock traded hands, compared to its average volume of 732,207. The stock has a 50 day moving average of $116.88 and a 200-day moving average of $106.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market cap of $29.54 billion, a PE ratio of -58.71 and a beta of 0.18. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 earnings per share. As a group, equities analysts expect that BioNTech SE will post -3.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BNTX shares. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective for the company. Berenberg Bank assumed coverage on BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price for the company. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a research note on Monday, December 2nd. HSBC upped their target price on BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Finally, JPMorgan Chase & Co. cut their target price on BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research note on Tuesday, November 26th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.